Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Anacor

- PMLiVE

Otezla scores new indication as speculation over potential buyers grows

Who will buy blockbuster psoriasis drug?

- PMLiVE

AstraZenca to appeal NICE rejection of Tagrisso

Pfizer’s Vizimpro wins recommendation

- PMLiVE

Rivals rise as safety issue mars Pfizer’s DMD gene therapy trial

Company to press ahead with phase 3 trial

- PMLiVE

Ex-FDA chief Gottlieb’s quick move to pharma raises eyebrows

Will join Pfizer board

- PMLiVE

AbbVie CEO Gonzalez defends Allergan takeover

Group's revenues will replace Humira loss

- PMLiVE

AbbVie to acquire Allergan for $63bn

Deal based on major cuts and diversified portfolio

Bristol Myers Squibb logo

Faced with regulator’s merger concerns, BMS want to offload Otezla

Sell-off will mean merger delay

- PMLiVE

Pfizer’s Talzenna cleared for breast cancer in Europe

Fourth to market aims to carve out niche

- PMLiVE

Pfizer adds Array to cancer arsenal with $11bn acquisition

Successful R&D teams to join Pfizer oncology network

- PMLiVE

Pfizer poaches cancer R&D head Jeff Settleman from Calico

Company gaining momentum in oncology

- PMLiVE

Amgen buys Danish partner Nuevolution for $167m

Copenhagen-based biotech will remain autonomous

- PMLiVE

Merck bulks up in cancer with $2.2bn Peloton buy

Another significant bolt-on in oncology

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links